CYTOKINETICS, INCORPORATED Other Employee-related Liabilities, Current
CYTOKINETICS, INCORPORATED (CYTK) had Other Employee-related Liabilities, Current of $2.21 million as of 2017-12-31, per its 10-K filed 2018-03-05.
Discontinued › Notes › Payables and Accruals › Accrued Liabilities, Current › Employee-related Liabilities, Current
us-gaap:OtherEmployeeRelatedLiabilitiesCurrent · last filed 2018-03-05
- 2017-12-31: Other Employee-related Liabilities, Current $2.21M.
- 2017-09-30: Other Employee-related Liabilities, Current $2.45M.
- 2017-06-30: Other Employee-related Liabilities, Current $2.15M.
- 2017-03-31: Other Employee-related Liabilities, Current $2.17M.
| Period end | Other Employee-related Liabilities, Current | Other Employee-related Liabilities, Current as first filed |
|---|---|---|
| 2017-12-31 | $2.21M 10-K · filed 2018-03-05 | |
| 2017-09-30 | $2.45M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $2.15M 10-Q · filed 2017-08-04 | |
| 2017-03-31 | $2.17M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $1.89M 10-K · filed 2018-03-05 | |
| 2015-12-31 | $1.46M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $1.02M 10-K · filed 2016-03-03 | $110.00K 10-K · filed 2015-03-06 |
| 2013-12-31 | $93.00K 10-K · filed 2015-03-06 | |
| 2012-12-31 | $87.00K 10-K · filed 2014-03-07 | |
| 2011-12-31 | $107.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |